Whereas other studies demonstrated that PRDX1 promoted tumor progression and metastasis through the activation of c-Jun, AP-1, and epithelial-mesenchymal transition in prostate, pancreatic, and colorectal cancers [19, 20]. Here, JUN is linked to neoplasm.